News and Trends 29 Sep 2015
Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?
Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]
